Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes

https://doi.org/10.1016/0009-2797(89)90061-6Get rights and content

Abstract

The cancer chemotherapeutic drug cis-diamminedichloroplatinum(II) (cis-DDP) is active as a result of its bifunctional reactions with DNA. Many other platinum complexes also have therapeutic activity. Of current interest are complexes containing 1,2-diaminocyclohexane (DACH). The DACH ligand exists in three isomeric forms with reported differences in therapeutic activity in the order R,R >S,S >R,S-DACH-Pt. The reaction of the sulphate form of each of these three isomers with DNA has been characterized as a possible explanation for the apparent differences in antitumor activity. These reactions have been characterized by platinating pure DNA followed by enzyme digestion, HPLC separation and analysis by atomic absorption and nuclear magnetic resonance. The spectrum of adducts produced was similar for each isomer and similar to that reported for cis-DDP with adduction at d(GpG), d(ApG) and (dG)2. The R,S-isomer additionally demonstrated isomeric adducts at d(GpG) and d(ApG). The kinetics of formation of the various adducts was the same for each isomer; total platination of DNA was complete in 15 min as were bifunctional adducts at d(GpG) and (dG)2. However, rearrangement to bifunctional adducts took several hours in the case of adducts at d(ApG) sequences. These results did not provide a reason for the different activities of the isomers. It is suggested that the interaction of these adducts with metabolic processes such as DNA repair might explain these differences.

References (20)

There are more references available in the full text version of this article.

Cited by (99)

  • Oxaliplatin and its derivatives – An overview

    2023, Coordination Chemistry Reviews
  • Platinum iodido complexes: A comprehensive overview of anticancer activity and mechanisms of action

    2019, Coordination Chemistry Reviews
    Citation Excerpt :

    Oxaliplatin was approved by FDA in 2002 and it is, in combination with 5-fluorouracil and leucovorin, used for the treatment of colorectal cancer naturally resistant to cisplatin. Mechanism of action of the platinum-based drugs is based on the intracellular hydrolysis (aquation) resulting in the displacement of the Cl−/cbdc/ox ligands (leaving groups) and formation of the positively charged aqua/hydroxido-species, capable to covalently attack the target DNA molecule, while the N-donor carrier ligands (NH3 or RRdach) remain intact during the described mechanistic processes [5–10]. Although the clinical success of cisplatin and its analogues is unprecedented, application of these drugs is connected with serious side effects (e.g., myelosuppression, nephrotoxicity or neurotoxicity) and with problems of both intrinsic and acquired resistance connected with the induction of protective cellular processes, including the cell accumulation and efflux, or Pt–DNA adduct recognition and repair [6,11–13].

  • Platinum complexes containing adenine-based ligands: An overview of selected structural features

    2017, Coordination Chemistry Reviews
    Citation Excerpt :

    Inagaki et al. studied the products of the reactions of [PtCl2(R,R-dach)] with dApG, dGpA, dpGpA and rGpA, which were identified by UV and CD spectroscopy after the HPLC separation as [Pt(R,R-dach)(dApG)-N1(1)N7(2)], [Pt(R,R-dach)(dApG)-N7(1)N7(2)], [Pt(R,R-dach)(dGpA)-N7(1)N1(2)], [Pt(R,R-dach)(dGpA)-N7(1)N7(2)], [Pt(R,R-dach)(dpGpA)-N7(1)N1(2)], [Pt(R,R-dach)(dpGpA)-N7(1)N7(2)], [Pt(R,R-dach)r(GpA)-N7(1)N1(2)] and [Pt(R,R-dach)r(GpA)-N7(1)N7(2)] [173]. The mentioned complex [Pt(R,R-dach)(dApG)-N7(1)N7(2)] [22,173–175] and its analogs involving other dach isomers {[Pt(R,S-dach)(dApG)-N7(1)N7(2)] and [Pt(S,S-dach)(dApG)-N7(1)N7(2)] [176]} and derivatives {[Pt(R,S,S-medach)(dApG)-N7(1)N7(2)] [177]} were also studied and described in the literature (medach = 3-methyl-1,2-diaminocyclohexane). The reaction of trans-[PtCl2(NH3)2] with DNA and enzymatic digestion of the product led to substances with compositions that were identified by NMR as [PtCl2(dCpT)-N3(2)-(dApG)-N1(1)], [PtCl2(dguo-N7)(dApT)-N1(1)], [PtCl2(dguo-N7)(dApC)-N1(1)], [PtCl2(dguo-N7)(dCpA)-N3(1)], [PtCl2(dguo-N7)(dApA)-N1(1)], and [PtCl2(dguo-N7)(dApG)-N1(1)] [43].

  • New binary and ternary platinum(II) formamidine complexes: Synthesis, characterization, structural studies and in-vitro antitumor activity

    2016, Journal of Molecular Structure
    Citation Excerpt :

    It contains diaminocyclohexane (carrier ligand) and oxalate (hydrolyzable ligand). It crosslinks at the nucleophilic sites on DNA of tumor cells [14,15] and inhibits RNA synthesis [16] thus inducing tumor cell death. Oxaliplatin has a broad spectrum of anti-tumor activity unlike cisplatin and carboplatin [17].

  • Effect of chirality in platinum drugs

    2015, Coordination Chemistry Reviews
View all citing articles on Scopus
View full text